• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Aldosterone breakthrough as a clue to the physiological importance of paracrine regulation of aldosterone secretion.

作者信息

Lopez Antoine-Guy, Louiset Estelle, Lefebvre Hervé

机构信息

UNIROUEN, Normandie University, INSERM, U1239, NorDiC, Rouen, France.

Department of Endocrinology, Diabetes and Metabolic Diseases, Rouen University Hospital, Rouen, France.

出版信息

Hypertens Res. 2022 Nov;45(11):1832-1834. doi: 10.1038/s41440-022-01009-9. Epub 2022 Aug 26.

DOI:10.1038/s41440-022-01009-9
PMID:36028626
Abstract
摘要

相似文献

1
Aldosterone breakthrough as a clue to the physiological importance of paracrine regulation of aldosterone secretion.醛固酮突破作为醛固酮分泌旁分泌调节生理重要性的线索。
Hypertens Res. 2022 Nov;45(11):1832-1834. doi: 10.1038/s41440-022-01009-9. Epub 2022 Aug 26.
2
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.糖尿病合并高血压患者在血管紧张素II受体阻滞剂治疗期间出现醛固酮突破现象。
Am J Hypertens. 2007 Dec;20(12):1329-33. doi: 10.1016/j.amjhyper.2007.09.001.
3
Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?肾素-血管紧张素系统（RAS）阻断期间的醛固酮突破：内皮素及其拮抗剂的作用？
Curr Hypertens Rep. 2006 Jun;8(3):262-8. doi: 10.1007/s11906-006-0060-5.
4
Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.免疫球蛋白A肾病蛋白尿患者在接受血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂治疗期间出现醛固酮突破。
Nephrology (Carlton). 2006 Oct;11(5):462-6. doi: 10.1111/j.1440-1797.2006.00665.x.
5
Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells.骨形态发生蛋白-6在肾上腺皮质细胞醛固酮调节中的作用。
Acta Med Okayama. 2010 Aug;64(4):213-8. doi: 10.18926/AMO/40128.
6
Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.在阿利吉仑、缬沙坦及联合用药（阿利吉仑+缬沙坦）治疗期间出现的醛固酮突破。
J Am Soc Hypertens. 2012 Sep-Oct;6(5):338-45. doi: 10.1016/j.jash.2012.07.003.
7
The incidence and implications of aldosterone breakthrough.醛固酮突破的发生率及影响
Nat Clin Pract Nephrol. 2007 Sep;3(9):486-92. doi: 10.1038/ncpneph0575.
8
Hypertension: renin-angiotensin-aldosterone system alterations.高血压：肾素-血管紧张素-醛固酮系统改变。
Circ Res. 2015 Mar 13;116(6):960-75. doi: 10.1161/CIRCRESAHA.116.303587.
9
Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions.人肾上腺皮质细胞中血管紧张素II 1型受体长期阻断导致醛固酮突破：骨形态发生蛋白-6作用的可能参与
Endocrinology. 2008 Jun;149(6):2816-25. doi: 10.1210/en.2007-1476. Epub 2008 Feb 28.
10
Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension.血管紧张素受体阻滞剂（ARB）或血管紧张素转换酶抑制剂（ACEI）给药对高血压患者血浆醛固酮和脂联素水平的影响
Int Heart J. 2009 Jul;50(4):501-12. doi: 10.1536/ihj.50.501.

引用本文的文献

1
Rationale and Design of a Randomized, Open-Label, Parallel-Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT-HT).依普利酮与血管紧张素受体阻滞剂治疗钙通道阻滞剂单药治疗血压控制不佳的老年患者的随机、开放标签、平行组研究（ESCORT-HT）的原理与设计
J Clin Hypertens (Greenwich). 2025 Jan;27(1):e14947. doi: 10.1111/jch.14947. Epub 2024 Nov 25.
2
Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker.依普利酮与三氯噻嗪对血压控制不佳的高血压患者的家庭血压降低效果：EXCITE-HT随机对照试验按基础钙通道阻滞剂与血管紧张素受体阻滞剂进行的预定义亚组分析
Hypertens Res. 2025 Feb;48(2):506-518. doi: 10.1038/s41440-024-01887-1. Epub 2024 Oct 12.
3

本文引用的文献

1
Aldosterone breakthrough from a pharmacological perspective.从药理学角度看醛固酮突破
Hypertens Res. 2022 Jun;45(6):967-975. doi: 10.1038/s41440-022-00913-4. Epub 2022 Apr 14.
2
The neuropeptide substance P regulates aldosterone secretion in human adrenals.神经肽 P 调节人肾上腺中的醛固酮分泌。
Nat Commun. 2020 May 29;11(1):2673. doi: 10.1038/s41467-020-16470-8.
3
Leptin and Aldosterone.瘦素与醛固酮
Reply to comments about "Aldosterone breakthrough".对关于“醛固酮突破”评论的回复。
Hypertens Res. 2023 May;46(5):1351-1352. doi: 10.1038/s41440-023-01235-9. Epub 2023 Feb 21.
Vitam Horm. 2019;109:265-284. doi: 10.1016/bs.vh.2018.09.003. Epub 2018 Dec 1.
4
Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.肥胖是特发性醛固酮增多症的关键致病因素。
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4456-4464. doi: 10.1210/jc.2018-00866.
5
Autocrine/paracrine regulatory mechanisms in adrenocortical neoplasms responsible for primary adrenal hypercorticism.促内泌/旁分泌调节机制在导致原发性肾上腺皮质功能亢进的肾上腺肿瘤中的作用。
Eur J Endocrinol. 2013 Oct 4;169(5):R115-38. doi: 10.1530/EJE-13-0308. Print 2013 Nov.
6
Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?肾素-血管紧张素系统（RAS）阻断期间的醛固酮突破：内皮素及其拮抗剂的作用？
Curr Hypertens Rep. 2006 Jun;8(3):262-8. doi: 10.1007/s11906-006-0060-5.
7
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.在糖尿病肾病患者推荐的抗高血压治疗中加用螺内酯的有益效果：一项随机、双盲、交叉研究。
Diabetes Care. 2005 Sep;28(9):2106-12. doi: 10.2337/diacare.28.9.2106.
8
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy.
Am J Hypertens. 2003 Sep;16(9 Pt 1):781-8. doi: 10.1016/s0895-7061(03)00913-0.
9
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.螺内酯对重度心力衰竭患者发病率和死亡率的影响。随机螺内酯评估研究调查组。
N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001.
10
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression.长期抑制血管紧张素II期间醛固酮血浆浓度升高。
J Endocrinol. 1981 Dec;91(3):457-65. doi: 10.1677/joe.0.0910457.